Feb 8 (Reuters) - Can-Fite Biopharma Ltd CANF.TA -
* Can-Fite gears up for acrobat, its phase III trial of piclidenoson in rheumatoid arthritis
* To commence patient enrollment in Q2 2017 in phase III trial of lead drug candidate piclidenoson for rheumatoid arthritis treatment
* Piclidenoson phase III trial, titled acrobat, will enroll approximately 500 patients in europe, canada and israel Source text for Eikon: ID:nPn8b8PJva Further company coverage: CANF.TA